Research Papers:

Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies

Rong Biaoxue _, Liu Hua, Gao Wenlong and Yang Shuanying

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:86902-86913. https://doi.org/10.18632/oncotarget.13509

Metrics: PDF 2258 views  |   HTML 2336 views  |   ?  


Rong Biaoxue1, Liu Hua2, Gao Wenlong3, Yang Shuanying4

1Department of Respiratory Medicine, First Affiliated Hospital, Xi’an Medical University, Xi’an, China

2Department of Respiratory Medicine, Gansu Provincial Hospital, Lanzhou, China

3Department of Statistics and Epidemiology, Medical College, Lanzhou University, Lanzhou, China

4Department of Respiratory Medicine, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, China

Correspondence to:

Rong Biaoxue, email: [email protected]

Keywords: icotinib, non-small cell lung cancer, NSCLC, meta-analysis, efficacy

Received: August 23, 2016     Accepted: November 08, 2016     Published: November 22, 2016


Icotinib is a new epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that developed and used in China; this work was to evaluate its efficacy and safety in treating non-small cell lung cancer (NSCLC). Clinical studies evaluating the efficacy and safety of icotinib in treating NSCLC were identified from the databases of Medline, Web of Science, Embase and Cochrance Library. Pooled efficacy and safety of icotinib were calculated through a series of predefined search strategies. A total of 15 studies with 2,304 patients were involved in this study. The overall response rate (ORR) and disease control rate (DCR) of icotinib were 40.99% (95% CI: 33.77% to 48.22%) and 77.16% (95% CI: 51.43% to 82.31%). The pooled progression-free survival (PFS) and overall survival (OS) were 7.34 months (95% CI: 5.60 to 9.07) and 14.98 months (95% CI: 9.78 to 20.18). Patients with EGFR mutations exhibited better ORR (OR = 3.67, p < 0.001), DCR (OR = 1.39, p = 0.001) and PFS (11.0 ± 0.76 vs. 1.97 ± 0.82 months). Moreover, patients with rash had a higher ORR (OR = 2.14, p = 0.001) than those without rash. The common adverse effects (AEs) included skin rash (31.4%), diarrhea (14.2%), pruritus (6.7%) and hepatic toxicity (3.8%) and most of them were well tolerated. In conclusion, Icotinib is an effective and well tolerated regimen for Chinese patients with advanced NSCLC. Further randomized trials with large population are required to provide stronger evidence for icotinib in treating NSCLC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13509